|
KMID : 0620920210530111689
|
|
Experimental & Molecular Medicine
2021 Volume.53 No. 11 p.1689 ~ p.1696
|
|
|
Disease-modifying therapeutic strategies in osteoarthritis: current status and future directions
|
|
Cho Yong-Sik
Jeong Su-Min
Kim Hyeon-Kyeong
Kang Dong-Hyun
Lee Jee-Yeon
Kang Seung-Baik
Kim Jin-Hong
|
|
|
Abstract
|
|
|
|
Osteoarthritis (OA) is the most common form of arthritis. It is characterized by progressive destruction of articular cartilage and the development of chronic pain and constitutes a considerable socioeconomic burden. Currently, pharmacological treatments mostly aim to relieve the OA symptoms associated with inflammation and pain. However, with increasing understanding of OA pathology, several potential therapeutic targets have been identified, enabling the development of disease-modifying OA drugs (DMOADs). By targeting inflammatory cytokines, matrix-degrading enzymes, the Wnt pathway, and OA-associated pain, DMOADs successfully modulate the degenerative changes in osteoarthritic cartilage. Moreover, regenerative approaches aim to counterbalance the loss of cartilage matrix by stimulating chondrogenesis in endogenous stem cells and matrix anabolism in chondrocytes. Emerging strategies include the development of senolytic drugs or RNA therapeutics to eliminate the cellular or molecular sources of factors driving OA. This review describes the current developmental status of DMOADs and the corresponding results from preclinical and clinical trials and discusses the potential of emerging therapeutic approaches to treat OA.
|
|
|
KEYWORD
|
|
|
Osteoarthritis, Translational research
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
    
|